Our Mission

NED Biosystems’™ corporate mission is to develop therapies and diagnostics to identify, monitor and treat complex chronic diseases with an initial focus on cancer. Currently, we seek to serve cancer patients to improve outcomes and quality of life while in treatment. We want to create therapies for both state-of-the-art healthcare systems as well as underserved populations in both developed and developing countries. We identify our key stakeholders as cancer patients and their families, employees, our shareholders, and all those who pay for cancer treatments.

Leadership

Rebecca Lambert
Founder and Executive Chairman

Rebecca Lambert, founder, has over 40 years of experience designing and executing strategies to solve complex issues confronting business, government, political, healthcare and financial entities. Since 2001 she has focused on development of NED lead candidate, NED-170, as a treatment for a wide range of cancer indications.

Prior to founding NED, Ms. Lambert had significant commercial successes leading an investment fund of more than $1B for Shaker Investments, and successfully launching groundbreaking telecommunications and media companies. Her Federal Government experience includes senior positions in support of political campaigns and sponsoring government policy and programs in Washington, including roles at the US Departments of Commerce, and Energy.

Ms. Lambert has a BA in political science from Simmons College and completed Harvard Business School’s Advanced Management Program. For five years she served as the President of Bellevue Hospital’s Bellevue Association Board.

Marc B. Blaustein, CFA
CEO, Board of Directors

Marc Blaustein has served as CEO of NED Biosystems since November 2017. Marc is a seasoned biopharmaceutical executive with more than 20 years of industry experience.  Most recently, he was a co-founder and CEO of Akashi Therapeutics, where he led the company from its inception through construction of a multi-product portfolio, generation of clinical data, and establishment of a strategic pharmaceutical partnership.  His prior experience encompasses leadership of key commercial, product development, business, and operations functions within biotechnology companies.  Previously, Marc held leadership roles at Dyax Corp (now Shire) including Senior VP Manufacturing, Process, and Commercial Operations, and led development of the now-marketed product Kalbitor®.  Prior to joining Dyax, Marc held business development and program management leadership roles at Alkermes, where he initiated and led the development program for the now-marketed product Vivitrol®.  Earlier, Marc joined Genetics Institute (now Pfizer) to head business development within the firm’s genomics business unit.

Before his career as a biopharmaceutical executive, Marc had a 10-year career in management consulting, first with Mercer Management Consulting (now Oliver Wyman), a global strategy consulting firm, and then as a founding partner of Northbridge Consulting.

Marc holds a Master’s Degree from Harvard University and BA in Biology from the University of Pennsylvania.  He is also a Chartered Financial Analyst (CFA) charterholder.

Peter D’Errico
Chief Financial Officer

Peter D’Errico has served as CFO since November 2017. Previously, he served as CEO at NED Biosystems from October 2009 to November 2017. Mr. D’Errico has over twenty years of senior level experience in building new technology businesses in the medical field. Prior to joining NED, Mr. D’Errico led the initial new product introductions in two commercial stage medical device companies (Eleme Medical & Aesthera). Mr. D’Errico was VP of Technical Operations with Cytyc Corp. (cancer diagnostic screening), where he led product development, technical support and operations. In medical devices, he was Executive Vice President of the Americas at Lumenis. Earlier, Mr. D’Errico held leadership positions in the Immunodiagnostics division of Chiron/Novartis for fifteen years. Mr. D’Errico served in various progressive roles including Managing Director, Chiron, UK, where he led 300 people in 5 countries and Vice President of Worldwide Marketing-Immunodiagnostics. Mr. D’Errico holds a Bachelors of Industrial Engineering from Kettering University and an MBA from Harvard Graduate School of Business Administration.

Edward Garmey, MD
Chief Medical Officer

Edward Garmey, M.D. serves as Chief Medical Officer at NED Biosystems.  Dr. Garmey is an oncology drug development consultant.  Dr. Garmey was formerly Chief Medical Officer and Senior Vice President at Cerulean Pharma, Inc., a clinical-stage oncology company based in Waltham, MA. focussed on the design and development of nanopharmaceutical-drug-conjugates differentially directed to cancer cells. Under his tenure at Cerulean, the company completed a successful IPO (NASDAQ:CERU) in April, 2014, and its clinical group, while increasing in size from one to 12 employees including three oncologist M.D.s, launched eight clinical trials and brought its second experimental drug into the clinic. Prior to being appointed to this role in 2011, Dr. Garmey served between 2008 and 2011 as Vice President for Clinical Development at ArQule, Inc., a publicly-traded cancer-focused biotechnology company located in Woburn, MA., where he developed and oversaw multiple international clinical trials of its lead product, ARQ 197 (tivantinib). Dr. Garmey additionally served there as a clinical development liaison with external development partners and assisted in the planning and execution of a license, co-development and co-commercialization agreement for the development of ARQ 197 in the United States and Europe. Prior to arriving at ArQule, Dr. Garmey was Medical Director at GPC Biotech in Princeton, New Jersey, where he helped oversee multiple global clinical development studies. A pediatric hematologist-oncologist by training,

Dr. Garmey is a graduate of Harvard and New York Universities and completed his medical training at the Mount Sinai Medical Center (N.Y.); the Children’s Hospital of Los Angeles; and the Memorial Sloan-Kettering Cancer Center (N.Y.). Dr. Garmey completed additional research fellowships at the National Institutes of Health (1998-99) and Botswana-Harvard Partnership for H.I.V. Research in Gaborone, Botswana (1999-2000) and he is a recipient of young investigators awards from the American Society of Hematology and the American Heart Association. Dr. Garmey has presented at numerous international conferences and is an author on over 50 peer-reviewed abstracts and manuscripts. In 2009, he was appointed as a medical consultant to the New York City Investment Fund’s $1.25 Million “BioAccelerate NYC Prize” for biomedical research. Additionally, in 2011, he was appointed to the scientific advisory board of the Harvard-MIT Broad Institute’s Cancer Vaccine Initiative. Dr. Garmey resides near Boston, Massachusetts, where he serves as an adjunct instructor at Harvard Medical School’s Therapeutics Graduate Program and additionally as a member of the Board of Overseers at the Beth Israel Deaconess Medical Center.

Beth Silverstein, MS, RAC

Beth has more than 25 years’ experience as a regulatory affairs professional, designing product development and regulatory strategies for pharmaceuticals, biologics, medical devices, and combination products and representing U.S. and international clients in FDA product approval efforts. Her broad expertise also includes the development of dietary supplements, and cosmetic ingredients. She has prepared or managed the preparation of INDs, NDAs, Annual Reports, Investigator Brochures, and Safety Reports for drug and combination products. She has prepared and successfully filed regulatory submissions for medical devices, including 510(k)s, IDEs for significant risk devices, and premarket approval PMA submissions for implantable devices. She has prepared several successful orphan drug designation requests and request for accelerated approval. She is currently a Director of SciLucent, a firm providing regulatory and scientific consulting services to the biopharmaceutical industry. Beth has an M.S. in Zoology (Physiology) from The Ohio State University and a B.S. in Biology from Binghamton University. She maintains Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

Gary Elliot, RPh, PharmD, PhD
CMC and Product Development

Dr. Elliott brings 33 years of experience in the biotechnology and pharmaceutical industry provide an experienced perspective in preclinical / manufacturing / pharmaceutical / quality, preclinical safety and clinical drug development strategic areas.  With a formal didactic, fellowship and employment background in pharmacy, clinical pharmacology, pharmaceutical sciences, medicinal chemistry, clinical research, and quality compliance, the consultant has guided overall drug development strategies for numerous pharmaceutical and biotech companies including: VP Product Development, Ribi ImmunoChem; Sr., Dir. Product Development, Corixa Corp; VP Product Development, Salmedix Inc.; Executive VP Product Development, Aires Pharmaceuticals; and VP Technical Operations, Adventrx Pharmaceuticals.

Dr. Elliott has had extensive interaction over the years with US, Canadian and European drug and biologics regulatory authorities, considerable experience authoring and supervising compilation of various regulatory filings spanning pre-IND to NDA. Consequently this consultant has developed comprehensive insight and appreciation of what are “development phase appropriate” levels of cGMP, cGLP and cGCP compliance

The consultant also provides critical review of in-licensing opportunities and competitive assessment of external drug candidates, allowing identification across clinical, CMC and preclinical areas of the strengths and weaknesses of such technologies.

Kristan Meetze, PhD
Drug Discovery, Pharmacology

Prior to joining NED Biosciences, Kristan served as the Head of Biology at Blend Therapeutics. Kristan was previously Head of Biology at Tarveda Therapeutics. Kristan served as Associate Director at AVEO Pharmaceuticals where she oversaw the pharmacology and preclinical development of AVEO’s antibody pipeline.  Previously, Kristan also served in scientific roles of increasing responsibility at both Millennium Pharmaceuticals and Eli Lilly & Co. Kristan received her PhD in cancer biology from Wayne State University, and a BS in Biochemistry from Susquehanna University.

Brenda Jarrell, PhD, JD
IP Counsel

Dr. Brenda Herschbach Jarrell PhD, JD, Co-Chair of the Life Sciences Group and Co-Chair of the Intellectual Property Department at Choate Hall & Stewart

Scientific Advisory Board

Edward Garmey, MD
Chief Medical Officer & Chairman of the Scientific Advisory Board

Edward Garmey, M.D. serves as Chief Medical Officer at NED Biosystems.  Dr. Garmey is an oncology drug development consultant.  Dr. Garmey was formerly Chief Medical Officer and Senior Vice President at Cerulean Pharma, Inc., a clinical-stage oncology company based in Waltham, MA. focussed on the design and development of nanopharmaceutical-drug-conjugates differentially directed to cancer cells. Under his tenure at Cerulean, the company completed a successful IPO (NASDAQ:CERU) in April, 2014, and its clinical group, while increasing in size from one to 12 employees including three oncologist M.D.s, launched eight clinical trials and brought its second experimental drug into the clinic. Prior to being appointed to this role in 2011, Dr. Garmey served between 2008 and 2011 as Vice President for Clinical Development at ArQule, Inc., a publicly-traded cancer-focused biotechnology company located in Woburn, MA., where he developed and oversaw multiple international clinical trials of its lead product, ARQ 197 (tivantinib). Dr. Garmey additionally served there as a clinical development liaison with external development partners and assisted in the planning and execution of a license, co-development and co-commercialization agreement for the development of ARQ 197 in the United States and Europe. Prior to arriving at ArQule, Dr. Garmey was Medical Director at GPC Biotech in Princeton, New Jersey, where he helped oversee multiple global clinical development studies. A pediatric hematologist-oncologist by training,

Dr. Garmey is a graduate of Harvard and New York Universities and completed his medical training at the Mount Sinai Medical Center (N.Y.); the Children’s Hospital of Los Angeles; and the Memorial Sloan-Kettering Cancer Center (N.Y.). Dr. Garmey completed additional research fellowships at the National Institutes of Health (1998-99) and Botswana-Harvard Partnership for H.I.V. Research in Gaborone, Botswana (1999-2000) and he is a recipient of young investigators awards from the American Society of Hematology and the American Heart Association. Dr. Garmey has presented at numerous international conferences and is an author on over 50 peer-reviewed abstracts and manuscripts. In 2009, he was appointed as a medical consultant to the New York City Investment Fund’s $1.25 Million “BioAccelerate NYC Prize” for biomedical research. Additionally, in 2011, he was appointed to the scientific advisory board of the Harvard-MIT Broad Institute’s Cancer Vaccine Initiative. Dr. Garmey resides near Boston, Massachusetts, where he serves as an adjunct instructor at Harvard Medical School’s Therapeutics Graduate Program and additionally as a member of the Board of Overseers at the Beth Israel Deaconess Medical Center.

Geoffrey Ling, MD, PhD, Col. (Ret.)

Dr. Geoffrey Ling serves as a Professor of Neurology at both Johns Hopkins University and the Uniformed Services University of the Health Sciences. He is an attending neurocritical care physician at Johns Hopkins Hospital and is board certified in both neurology and neurocritical care. He also is CEO of SunQ, LLC, which is a firm specializing in technology development for healthcare. He previously served as the Founding Director of the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA) and also Assistant Director for Medical Innovation of the Science Division in President Obama’s White House Office of Science and Technology Policy.  He is a retired U.S. Army colonel, who served for 27 years during which time he was deployed to Iraq and Afghanistan.
Dr. Ling’s medical degree is from Georgetown University and his doctorate in Pharmacology from Cornell University. He was a post-doctoral research fellow at Memorial Sloan Kettering Cancer Center. His neurology residency was done at Walter Reed Army Medical Center and his Neuro Critical Care fellowship at Johns Hopkins.  He has published over 200 peer-reviewed articles, book chapters and reviews.  He is a member of the honor societies of Alpha Omega Alpha, Sigma Xi and Military Medical Order of Merit. He is a fellow of the American Neurological Association, American Association of Neurology and Neurocritical Care Society. He is a member of the Society for Critical Care Medicine, American Society of Pharmacology and Experimental Therapeutics and AMSUS (the Society of Federal Health Professionals).

Marsha A. Moses, PhD

Julia Dyckman Andrus Professor
Harvard Medical School
Director, Vascular Biology Program
Boston Children’s Hospital
Department of Surgery

Dr. Marsha A. Moses is the Julia Dyckman Andrus Professor at Harvard Medical School and the Director of the Vascular Biology Program at Boston Children’s Hospital. She has made significant contributions to our understanding of the biochemical and molecular mechanisms that underlie the regulation of tumor growth and progression. Dr. Moses and her laboratory have discovered a number of inhibitors of neovascularization that function at both the transcriptional and translational level, some of which are in preclinical testing. Named a pioneer in the field of Biomarker Medicine by the Journal of the National Cancer Institute, Dr. Moses established a Proteomics Initiative in her laboratory to complement this work which has led to the discovery of panels of noninvasive urinary cancer biomarkers that can predict disease status and stage in cancer patients and that are sensitive and accurate markers of disease progression and therapeutic efficacy of cancer drugs. A number of these biomarkers are being used in clinical trials. To further complement her basic and translational findings above, Marsha and her team have developed non-toxic, targeted nanomedicines for the treatment of human cancers and their metastases. These drug delivery systems are engineered to deliver a variety of therapeutic agents including, siRNAs, chemotherapies and gene editing systems. These diagnostics and potential therapeutics are included in Dr. Moses’ significant patent portfolio composed of both US and foreign patents.

Dr. Moses’ basic and translational work has been published in such journals as Science, the New England Journal of Medicine, Cell and the Journal of Biological Chemistry, among others. Marsha received a Ph.D. in Biochemistry from Boston University and completed a National Institutes of Health postdoctoral fellowship at Boston Children’s Hospital and MIT in the laboratory of Dr. Robert Langer. She is the recipient of a number of NIH and foundation grants and awards. Dr. Moses has been recognized with both of Harvard Medical School’s mentoring awards, the A. Clifford Barger Mentoring Award (2003) and the Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty (2009). In 2014, she received the Excellence in Mentoring Award from the Postdoc Association of Boston Children’s Hospital and in 2016, she received their award for Exceptional Mentorship. In 2013, Dr. Moses received the Honorary Member Mentoring Award from the Association of Women Surgeons of the American College of Surgeons.  Dr. Moses was elected to the Institute of Medicine (National Academy of Medicine) of the National Academies of the United States in 2008 and to the National Academy of Inventors in 2013.

Robert S. Kerbel, PhD

Professor, University of Toronto
Senior Scientist, Sunnybrook Health Services Center

Dr. Robert Kerbel received his PhD in immunology in 1972 from the Dept. of Immunology & Microbiology, Queen’s University, Kingston, Ontario, Canada, after which he undertook postdoctoral training in London at the Institute for Cancer Research in tumor immunology. He started his independent research program in 1975 studying tumor immunology and metastasis at Queen’s, and was appointed Director of the Cancer Biology Program in the Dept. of Pathology in 1981. In 1985 he was recruited as Director of Cancer Biology Research at Mt. Sinai Hospital, Toronto. He then moved to Sunnybrook Health Sciences Centre to assume the same position from 1991 until 2001.

Dr. Kerbel held a Canada Research Chair in Tumor Biology, Angiogenesis & Antiangiogenic Therapy (2001-2015), and is a professor in the Dept. of Medical Biophysics at the University of Toronto, and Senior Scientist at the Sunnybrook Research Institute. His overall main research interest has been devising new cancer treatment strategies having improved efficacy and reduced toxicity for the treatment of metastatic disease. This culminated in his translational studies of combinatorial low-dose ‘metronomic’ chemotherapy with antiangiogenic drugs. Other major contributions include development of improved preclinical investigational therapeutic models in mice involving early stage or advanced metastatic disease, linking the fields of angiogenesis and oncogenes, uncovering mechanisms by which antiangiogenic drugs increase chemotherapy efficacy, and elucidating mechanisms of intrinsic or acquired antiangiogenic drug resistance. His current major research interests include assessment of ‘vessel co-option’ in tumors on response to antiangiogenic drugs, and combination therapy utilizing immune checkpoint inhibitors with VEGF (or ang2) targeting antiangiogenic drugs, using new mouse models for immune therapy his lab is developing.

Dr. Kerbel has published 417 papers, given 862 invited lectures around the world. He is and has been an editorial board member of numerous international scientific journals. Currently these include Molecular Cancer Therapeutics, EMBO Molecular Medicine, and the International Journal of Cancer. Among the awards he has received include the 2004 Canadian Cancer Society Robert Noble Award for Excellence in Cancer Research, the Breast Cancer Research Award from the European Institute of Oncology in 2008, a Man of Distinction Honor by the Israel Cancer Research Fund in 2011, and the Colin Thomson Memorial Medal for achievements in cancer research from Worldwide Cancer Research (formerly known as the Association for International Cancer Research) in 2013. His research studies have been supported by numerous agencies including the National Institutes of Health, USA, the Canadian Cancer Society Research Institute, the Canadian Institutes of Health Research, the Canadian Breast Cancer Foundation, and Worldwide Cancer Research. He also collaborated extensively with industry and has consulted for over 20 pharmaceutical and biotech companies during the last 25 years.

Judith E. Karp, MD

Professor Emerita of Oncology and Medicine
The Johns Hopkins University School of Medicine, Baltimore, MD

Dr. Judith Karp, MD is a Professor Emerita of Oncology and Medicine at Johns Hopkins University School of Medicine where she was Professor of oncology and Director of the Adult Leukemia Program in the Division of Hematologic Malignancies at The Sidney Kimmel Comprehensive Cancer Center, until 2013. Dr. Karp’s primary clinical interest is the experimental therapeutics of acute leukemias. She has authored 275 peer-reviewed articles and 35 book chapters, and edited 2 textbooks on acute leukemias, most recently ​an innovative textbook entitled “Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment.” Dr. Karp maintains active involvement with former fellows and faculty in terms of clinical trials development, design and analysis, and serves on the central IRB for the National Cancer Institute and is Chairman of the DSMC for The Leukemia & Lymphoma Society Beat AML Umbrella Clinical Trial and for the Tolero Phase II Biomarker-Driven Study of the Cyclin Dependent Kinase Inhibitor Alvocidib. She has received the Dr. John J. Kenny and Spiral of Life Awards from the Leukemia Lymphoma Society.

Dudley R. Herschbach, PhD

Frank B. Baird Jr. Professor Emerita of Science
Harvard University, Cambridge, MA
Nobel Prize Recipient in Chemistry, 1986

Dr. Dudley Herschbach is the Frank B. Baird Jr. Professor of Science, Emeritus at Harvard University. Born in San Jose, California, he obtained a B.S. in Mathematics (1954) and M. S. in Chemistry (1955) at Stanford, followed by an A.M. degree in Physics (1956) and Ph.D. in Chemical Physics (1958). He joined the chemistry faculty at the University of California, Berkeley (1959), where he launched novel molecular beam experiments to probe reaction dynamics in single collisions. He returned to Harvard (1963), expanding the beam experiments and much else over the next four decades. He taught a wide range of courses, graduate and undergraduate, including freshman chemistry for 20 years, his most challenging assignment. After becoming emeritus (2003) he continued teaching a freshman seminar (up to 2011, titled: “Molecular Motors: Wizards of the Nanoworld”). He also enjoyed some visiting appointments, especially in physics at Texas A & M University (2005-2017).

His efforts to enhance science education and public understanding centered for many years with the Society for Science and the Public, which publishes Science News and conducts the Science Talent Search and the International Science and Engineering Fair. He long-chaired the Hans Bethe Center for Arms Control and Nonproliferation, and is a Life member of Friends of Benjamin Franklin and of The Sierra Club.

Honors include the Nobel Prize (1986), shared with Yuan Lee and John Polanyi.  Among others much appreciated are Honorary Life Member of the Association of Women Scientists (1998); and three prizes named for him: Harvard Chemistry Teaching Prize for Graduate Students; Harvard University Teacher/Scientist Lectureship; and a Molecular Dynamics Prize.

Board of Directors

Rebecca Lambert
Founder & Executive Chairman of the Board of Directors

Rebecca Lambert, founder, has over 40 years of experience designing and executing strategies to solve complex issues confronting business, government, political, healthcare and financial entities. Since 2001 she has focused on development of NED lead candidate, NED-170, as a treatment for a wide range of cancer indications.

Prior to founding NED, Ms. Lambert had significant commercial successes leading an investment fund of more than $1B for Shaker Investments, and successfully launching groundbreaking telecommunications and media companies. Her Federal Government experience includes senior positions in support of political campaigns and sponsoring government policy and programs in Washington, including roles at the US Departments of Commerce, and Energy.

Ms. Lambert has a BA in political science from Simmons College and completed Harvard Business School’s Advanced Management Program. For five years she served as the President of Bellevue Hospital’s Bellevue Association Board.

Josh Kopelman

Forbes 2016 “The Midas List”: #6
A staple of the top of the Midas List now in his sixth year in the top 20, Josh Kopelman stands out as a pioneer of a group of top seed-stage investors once called the ‘super angels’ after Kopelman co-founded First Round Capital in 2004.” –Forbes

Co-Founder, First Round Capital, which has re-invented seed-stage investing with early investments in Blue Apron, Uber, Square, Warby Parker, LinkedIn and NED Biosystems.

Josh has been an active entrepreneur and investor in the Internet industry since its commercialization.

Josh co-founded First Round Capital in 2004 to reinvent seed-stage investing. Since that time, the firm has invested in over 300 emerging technology startups – becoming one of the most active venture capital firms in the country. Josh has consistently made the Forbes “Midas List” which ranks the top 100 tech investors, earning the number four spot in 2014. Josh has been named one of the top ten ‘angel investors’ in the United States by Newsweek magazine, one of “Tech’s New Kingmakers” by Business 2.0 magazine and a “Rising VC Star” by Fortune magazine.

Prior to founding First Round, Josh co-founded three companies: Infonautics Corporation (IPO 1996), Half.com (acquired by eBay in 2000), and TurnTide (acquired by Symantic in 2003). Josh is an inventor on 13 U.S. Patents for his work in Internet technology. In June 2000, he was awarded Ernst and Young’s prestigious “Entrepreneur of the Year” award for the Greater Philadelphia region. Josh earned a Bachelor of Science degree cum laude in Entrepreneurial Management and Marketing from The Wharton School of the University of Pennsylvania.

Marc B. Blaustein, CFA
CEO

Marc Blaustein has served as CEO of NED Biosystems since November 2017. Marc is a seasoned biopharmaceutical executive with more than 20 years of industry experience.  Most recently, he was a co-founder and CEO of Akashi Therapeutics, where he led the company from its inception through construction of a multi-product portfolio, generation of clinical data, and establishment of a strategic pharmaceutical partnership.  His prior experience encompasses leadership of key commercial, product development, business, and operations functions within biotechnology companies.  Previously, Marc held leadership roles at Dyax Corp (now Shire) including Senior VP Manufacturing, Process, and Commercial Operations, and led development of the now-marketed product Kalbitor®.  Prior to joining Dyax, Marc held business development and program management leadership roles at Alkermes, where he initiated and led the development program for the now-marketed product Vivitrol®.  Earlier, Marc joined Genetics Institute (now Pfizer) to head business development within the firm’s genomics business unit.

Before his career as a biopharmaceutical executive, Marc had a 10-year career in management consulting, first with Mercer Management Consulting (now Oliver Wyman), a global strategy consulting firm, and then as a founding partner of Northbridge Consulting.

Marc holds a Master’s Degree from Harvard University and BA in Biology from the University of Pennsylvania.  He is also a Chartered Financial Analyst (CFA) charterholder.

Geoffrey Ling, MD, PhD, Col. (Ret.)

Dr. Geoffrey Ling serves as a Professor of Neurology at both Johns Hopkins University and the Uniformed Services University of the Health Sciences. He is an attending neurocritical care physician at Johns Hopkins Hospital and is board certified in both neurology and neurocritical care. He also is CEO of SunQ, LLC, which is a firm specializing in technology development for healthcare. He previously served as the Founding Director of the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA) and also Assistant Director for Medical Innovation of the Science Division in President Obama’s White House Office of Science and Technology Policy.  He is a retired U.S. Army colonel, who served for 27 years during which time he was deployed to Iraq and Afghanistan.
Dr. Ling’s medical degree is from Georgetown University and his doctorate in Pharmacology from Cornell University. He was a post-doctoral research fellow at Memorial Sloan Kettering Cancer Center. His neurology residency was done at Walter Reed Army Medical Center and his Neuro Critical Care fellowship at Johns Hopkins.  He has published over 200 peer-reviewed articles, book chapters and reviews.  He is a member of the honor societies of Alpha Omega Alpha, Sigma Xi and Military Medical Order of Merit. He is a fellow of the American Neurological Association, American Association of Neurology and Neurocritical Care Society. He is a member of the Society for Critical Care Medicine, American Society of Pharmacology and Experimental Therapeutics and AMSUS (the Society of Federal Health Professionals).

Mary Davis

Ms. Mary Graham Davis brings extensive experience in effective organizational structure, business alignment and performance management, senior leadership coaching, and strategic directional change.

Davis is a senior managing director of Brock Capital Group LLC and founded the Davis Consulting Group LLC in 1996. She retired as the Chair of the Board of Trustees of Mount Holyoke College in 2015.

Davis previously served as managing vice president for PeopleTech, where she consulted to U.S. and global organizations implementing change processes resulting from restructuring, high growth opportunities or leadership transitions. Prior to the acquisition by Right, she served as the vice chair of Jannotta, Bray and Associates, head of the Jannotta Consulting Group, and managing director of their New York Metropolitan Area Operating Group. She began her career with CITICORP in the overseas equity investment Edge Act subsidiary.

Previous board positions include president of the Alumnae Association of Mount Holyoke College, president of the Graham-Windham Services to Families and Children in New York; and member of the Winnetka Public Schools Board of Education.

Davis has a B.A. from Mount Holyoke College and a master’s degree in international economics from the Fletcher School of Law and Diplomacy, a joint program by Harvard & Tufts Universities.

Randy Barko

Mr. Barko is currently President and CEO of Ximedica, LLC.  Mr. Barko has over 35 years experience leading medical device and healthcare organizations towards global and financial growth. Mr. Barko has served as the President and Chief Executive Officer of Ximedica, LLC since April 2012. Mr. Barko is a board member of the AdvaMed Emerging Growth Company Council. Currently Mr. Barko serves on the Board of Directors of several other privately owned companies and is involved with several private equity and venture capital groups. In addition, he was named to the AdvaMed Accel and MassMEDIC Board in 2014.

Prior to these roles, Mr. Barko was Vice President of Corporate Development at Flextronics (NASDAQ:FLEX) and was Corporate Vice President, Marketing & Business Development and member of the Board of Directors at Nypro Inc. During his 25 years with Nypro he was responsible for the business teams that led to steady growth in annual sales from $40 million to $1 billion. Mr. Barko was also President & CEO of the Nypro Medical Products Group and Chairman of NP Medical Inc. He held senior management positions at Hallmark Plastics in Buffalo, New York and Peninsula Plastics in Erie, Pennsylvania. Mr. Barko graduated from the University of Notre Dame and also completed numerous executive leadership programs including Duke University Fuqua Business School, Dartmouth College Amos Tuck Business School, University of Limerick Ireland, Central European University of Hungary and The National University of Singapore.

“I feel confident with the NED-170 therapy that I am managing my cancer without surgery and without side effects”

– Prostate Cancer Patient on NED-170.

Not actual patient photo

An Unmet Global Need

Cancer is a critical health problem in the U.S. where it is the second leading cause of death, accounting for about 600,000 annual fatalities. But the ravages of cancer are even worse in the developing world:

  • Cancer kills 50% more people in developing countries than HIV, malaria, and TB combined;
  • Africa, Asia and Central and South America together account for 70% of the world’s cancer deaths¹;
  • 80% of cancer patients in Africa are diagnosed at advanced stages, with pain relief as the only treatment; and,
  • In developing countries, very few patients ever receive cancer treatments because today’s drugs require medical infrastructure (e.g., cold supply chain, infusion centers, medical management of severe toxicities).

NED-170 promises to fill an unmet need in developing countries. As an oral therapy we expect to be well-tolerated, NED-170 will not require cold supply chain or other “traditional” cancer medical infrastructure. We believe NED-170 will be a viable therapy for developing world patients suffering from a broad range of cancers. As part of our corporate mission, NED is committed to supplying NED-170 to patients in the developing world at-cost plus less than 10%.

¹World Health Organization

US-AFRICOM